Sohini Das, Anjali Singh

Stories by Sohini Das, Anjali Singh

Bajaj Chetak Takes the Slow Road To Global Reach

Bajaj Chetak Takes the Slow Road To Global Reach

Rediff.com   15 Jan 2026

Bajaj Auto is planning a slow, calibrated push to take the Chetak, its electric scooter, to more than 100 countries on the strength of its distributor network and market-specific localisation rather than an aggressive global rollout, reports Sohini Das.

Mercedes-Benz Hits Speed Bump In 2025, Vows To Stay Course

Mercedes-Benz Hits Speed Bump In 2025, Vows To Stay Course

Rediff.com   15 Jan 2026

Despite a 2.8 per cent fall in 2025 volumes, Mercedes-Benz India reported its best-ever revenue and profitability, led by top-end models, AMG growth and higher BEV mix.

Maruti Dzire is top-selling car of 2025!

Maruti Dzire is top-selling car of 2025!

Rediff.com   13 Jan 2026

It is after seven years that a sedan has claimed the top spot -- Dzire had last achieved the No.1 position in 2018.

SUVs rule resale market despite small cars getting cheaper

SUVs rule resale market despite small cars getting cheaper

Rediff.com   13 Jan 2026

Data from used-car platforms suggest that buyer preferences have remained broadly stable post-GST, with SUVs retaining their dominance even as price adjustments played out across segments.

Carmakers Go Deep In Bid To Expand Beyond Metros

Carmakers Go Deep In Bid To Expand Beyond Metros

Rediff.com   12 Jan 2026

Network scale seen as central to tapping smaller markets.

Healthcare IPOs See A Surge In 2025

Healthcare IPOs See A Surge In 2025

Rediff.com   8 Jan 2026

The surge has come alongside a decline in average issue sizes and more muted listing-day returns compared with last year.

Tata Motors leads EV pack in 2025, but pecking order could change

Tata Motors leads EV pack in 2025, but pecking order could change

Rediff.com   8 Jan 2026

Mahindra and Mahindra (M&M) recorded the sharpest acceleration among large players, with EV retail jumping to 33,513 units from 7,139 units, an almost 5-fold jump, aided by strong demand for new launches.

Indian pharma companies see sharp drop in adverse USFDA findings in 2025

Indian pharma companies see sharp drop in adverse USFDA findings in 2025

Rediff.com   8 Jan 2026

The US Food and Drug Administration (USFDA) recorded a significant decline in serious regulatory findings at Indian drug manufacturing facilities between January and December 2025. Data reveals that 'official action indicated' (OAI) cases - the most severe classification - nearly halved over the past year.

Simple Energy debuts Gen 2 e-scooters to drive 2026 growth

Simple Energy debuts Gen 2 e-scooters to drive 2026 growth

Rediff.com   6 Jan 2026

'This is not just a cosmetic refresh,' said Suhas Rajkumar, founder and chief executive officer of Simple Energy. 'We have re-engineered the battery integration, made the scooter lighter, improved performance and expanded the portfolio so customers can choose based on real usage needs.'

India's diagnostic chains are in expansion mode. Here's why

India's diagnostic chains are in expansion mode. Here's why

Rediff.com   29 Dec 2025

India's diagnostics sector is accelerating capacity addition and geographic expansion, as large chains and regional players invest in new laboratories, integrated centres and dense sample collection networks to tap rising demand for preventive, advanced and precision testing.

Carmakers Gear Up To Hit Refresh Button

Carmakers Gear Up To Hit Refresh Button

Rediff.com   27 Dec 2025

'In India's competitive automotive market, staying relevant means continuously raising the bar.'

Cancer Therapies Break New Ground

Cancer Therapies Break New Ground

Rediff.com   26 Dec 2025

'India is clearly moving toward more targeted treatment pathways in high-burden cancers.'

Emcure sets sights on pan-Indian obesity market with Poviztra

Emcure sets sights on pan-Indian obesity market with Poviztra

Rediff.com   23 Dec 2025

Emcure Pharmaceuticals on Monday said it saw Poviztra, its newly launched semaglutide brand, as a "long-term" opportunity in India's fast-evolving obesity and cardiometabolic therapy market, even as price competition in the glucagon-like peptide-1 (GLP-1) segment intensified.

Why Carmakers Are Reviving Old Names

Why Carmakers Are Reviving Old Names

Rediff.com   16 Dec 2025

Indian automakers are reviving legacy nameplates to leverage brand recall and stand out in a crowded market, as classic badges like Sierra, Safari, Baleno and Scorpio return to attract buyers.

2026 will see launch of over 25 new cars

2026 will see launch of over 25 new cars

Rediff.com   15 Dec 2025

Starting January, the market is expected to welcome models like the Tata Punch 2025 which is expected to be around 6 lakh, Mahindra BE 07 EV around 29 lakh, Maruti WagonR Electric around 8.5 lakh, Toyota 3-Row SUV around 14 lakh, and Volkswagen Tera to be around 8 lakh.

GST 2.0 boosts petrol-diesel car sales over EVs

GST 2.0 boosts petrol-diesel car sales over EVs

Rediff.com   10 Dec 2025

While GST on ICE vehicles was brought down significantly, for electric cars it remained at 5 per cent.

GST 2.0 Puts Luxury Cars In Fast Lane

GST 2.0 Puts Luxury Cars In Fast Lane

Rediff.com   10 Dec 2025

India's luxury auto market is rebounding after a slow start to 2025, with GST 2.0 emerging as the main catalyst.

50 Mn To 100 Mn Indians Suffer From Long Covid

50 Mn To 100 Mn Indians Suffer From Long Covid

Rediff.com   2 Dec 2025

Even by conservative assumptions that 5 to 10 per cent of infected individuals develop long Covid, India today may be home to 50 to 100 million infected individuals -- many silently coping with breathlessness, fatigue, palpitations, brain fog, or unexplained clotting tendencies.

Mahindra To Build 1000 Ultra-Fast Charging Points On Highways

Mahindra To Build 1000 Ultra-Fast Charging Points On Highways

Rediff.com   1 Dec 2025

Mahindra & Mahindra (M&M) is stepping beyond vehicle manufacturing to build a national electric-mobility ecosystem.

Seniors to Drive 25% of India's Pharma

Seniors to Drive 25% of India's Pharma

Rediff.com   21 Nov 2025

'Once the 60-plus population hits 20 to 30 per cent of the country, the demand for elderly-care treatments will surge -- cardiac, metabolic, neurological, and musculoskeletal medicines are going to dominate the market for the next several decades.'